CN113164626A - 嵌合受体多肽及其用途 - Google Patents

嵌合受体多肽及其用途 Download PDF

Info

Publication number
CN113164626A
CN113164626A CN202080006993.7A CN202080006993A CN113164626A CN 113164626 A CN113164626 A CN 113164626A CN 202080006993 A CN202080006993 A CN 202080006993A CN 113164626 A CN113164626 A CN 113164626A
Authority
CN
China
Prior art keywords
tcr
domain
chimeric receptor
extracellular
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080006993.7A
Other languages
English (en)
Chinese (zh)
Inventor
曾明
张辉辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Legend Biotechnology Co Ltd
Original Assignee
Nanjing Legend Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotechnology Co Ltd filed Critical Nanjing Legend Biotechnology Co Ltd
Publication of CN113164626A publication Critical patent/CN113164626A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080006993.7A 2019-01-14 2020-01-14 嵌合受体多肽及其用途 Pending CN113164626A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019071609 2019-01-14
CNPCT/CN2019/071609 2019-01-14
PCT/CN2020/071947 WO2020147708A1 (en) 2019-01-14 2020-01-14 Chimeric receptor polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CN113164626A true CN113164626A (zh) 2021-07-23

Family

ID=71614406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080006993.7A Pending CN113164626A (zh) 2019-01-14 2020-01-14 嵌合受体多肽及其用途

Country Status (9)

Country Link
US (1) US20230192805A1 (enExample)
EP (1) EP3911370A4 (enExample)
JP (1) JP2022516496A (enExample)
KR (1) KR20210116478A (enExample)
CN (1) CN113164626A (enExample)
AU (1) AU2020208110A1 (enExample)
CA (1) CA3126422A1 (enExample)
SG (1) SG11202106257WA (enExample)
WO (1) WO2020147708A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114560949A (zh) * 2022-03-07 2022-05-31 中国人民解放军空军军医大学 一种具有增强car-t细胞抗肿瘤能力的嵌合抗原受体、d-car-t细胞及其应用
CN114560948A (zh) * 2022-03-07 2022-05-31 中国人民解放军空军军医大学 一种嵌合抗原受体、car-t细胞及其应用
CN114573712A (zh) * 2022-03-07 2022-06-03 中国人民解放军空军军医大学 一种嵌合抗原受体、car-t细胞及其应用
WO2023193800A1 (zh) * 2022-04-07 2023-10-12 恺兴生命科技(上海)有限公司 嵌合多肽及其应用
CN117074674A (zh) * 2023-03-23 2023-11-17 武汉勖瑞生物科技有限责任公司 检测N-乙酰-β-D氨基葡萄糖苷酶的胶体金试纸及其制备方法
WO2024140981A1 (zh) * 2022-12-30 2024-07-04 上药生物治疗（香港）有限公司 细胞原位分泌抗体及其用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2022228579A1 (en) * 2021-04-30 2022-11-03 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting gpc3 and methods of use thereof
WO2023274382A1 (zh) * 2021-06-30 2023-01-05 华夏英泰（北京）生物技术有限公司 一种多靶点合成t细胞受体抗原/抗体受体及其应用
EP4370541A1 (en) * 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023164698A2 (en) * 2022-02-27 2023-08-31 Health Research, Inc. FOLATE RECEPTOR ALPHA -TARGETING BI-SPECIFIC T CELL ENGAGERS (BiTEs) AND USES THEREOF
AR130387A1 (es) * 2022-09-08 2024-12-04 Hoffmann La Roche Receptores de linfocitos t recombinantes
WO2024100136A1 (en) * 2022-11-08 2024-05-16 Gadeta B.V. Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024140710A1 (zh) * 2022-12-26 2024-07-04 华夏英泰（北京）生物技术有限公司 一种特异性结合lilrb4的合成t细胞受体抗原受体及其应用
US20260234216A1 (en) * 2023-03-30 2026-08-13 Yale University Universal antibody receptors, guar-t cells and therapeutic use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016094304A2 (en) * 2014-12-12 2016-06-16 Bluebird Bio, Inc. Bcma chimeric antigen receptors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CN105555804B (zh) * 2013-08-07 2020-12-25 阿菲姆德股份有限公司 对EGFRvIII有特异性的抗体结合位点
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
US20170335009A1 (en) * 2014-10-31 2017-11-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tetravalent tlr9 bispecific antibody
EP3770168A1 (en) * 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201604953D0 (en) * 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
CN105777911B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
US20190375815A1 (en) * 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018200582A1 (en) * 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016094304A2 (en) * 2014-12-12 2016-06-16 Bluebird Bio, Inc. Bcma chimeric antigen receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DINA SCHNEIDER等: "A Tandem CD19/CD20 CAR Lentiviral Vector Drives On-Target and Off-Target Antigen Modulation in Leukemia Cell Lines" *
KEVIN M. FRIEDMAN等: "Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells" *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114560949A (zh) * 2022-03-07 2022-05-31 中国人民解放军空军军医大学 一种具有增强car-t细胞抗肿瘤能力的嵌合抗原受体、d-car-t细胞及其应用
CN114560948A (zh) * 2022-03-07 2022-05-31 中国人民解放军空军军医大学 一种嵌合抗原受体、car-t细胞及其应用
CN114573712A (zh) * 2022-03-07 2022-06-03 中国人民解放军空军军医大学 一种嵌合抗原受体、car-t细胞及其应用
CN114560949B (zh) * 2022-03-07 2023-09-26 中国人民解放军空军军医大学 一种具有增强car-t细胞抗肿瘤能力的嵌合抗原受体、d-car-t细胞及其应用
WO2023193800A1 (zh) * 2022-04-07 2023-10-12 恺兴生命科技(上海)有限公司 嵌合多肽及其应用
WO2024140981A1 (zh) * 2022-12-30 2024-07-04 上药生物治疗（香港）有限公司 细胞原位分泌抗体及其用途
CN117074674A (zh) * 2023-03-23 2023-11-17 武汉勖瑞生物科技有限责任公司 检测N-乙酰-β-D氨基葡萄糖苷酶的胶体金试纸及其制备方法
CN117074674B (zh) * 2023-03-23 2024-01-23 武汉勖瑞生物科技有限责任公司 检测N-乙酰-β-D氨基葡萄糖苷酶的胶体金试纸及其制备方法

Also Published As

Publication number Publication date
CA3126422A1 (en) 2020-07-23
US20230192805A1 (en) 2023-06-22
EP3911370A4 (en) 2022-10-26
AU2020208110A1 (en) 2021-07-15
JP2022516496A (ja) 2022-02-28
WO2020147708A1 (en) 2020-07-23
EP3911370A1 (en) 2021-11-24
KR20210116478A (ko) 2021-09-27
SG11202106257WA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
WO2020147708A1 (en) Chimeric receptor polypeptides and uses thereof
US10822413B2 (en) Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
US12473345B2 (en) Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
JP7034934B2 (ja) キメラ抗原及びｔ細胞受容体、並びに使用方法
JP2021094037A (ja) 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2021501606A (ja) Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
JP2019537429A (ja) 細胞によって発現される生物活性を調節する結合分子
CN116059316A (zh) 抗体/t细胞受体嵌合构建体及其用途
CN115989033B (zh) 用于使用cd70特异性融合蛋白进行tcr重编程的组合物和方法
JP7690597B2 (ja) 免疫細胞機能の改善
JP2022535410A (ja) Ｔａｃｉを標的とする抗体及びキメラ抗原受容体
KR20240004680A (ko) 키메라 수용체 및 이의 사용 방법
TWI888376B (zh) 辨識抗體改變部位之嵌合受體
JP2025538171A (ja) 抗原結合ドメイン及びその使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination